An investigation on behalf of investors in Accelerate Diagnostics, Inc. (NASDAQ: AXDX) shares over potential wrongdoing at Accelerate Diagnostics, Inc. was announced and NASDAQ: AXDX stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 01/23/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Accelerate Diagnostics, Inc.
Investors who purchased shares of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Accelerate Diagnostics, directors breached their fiduciary duties and caused damage to the company and its shareholders.
Tucson, AZ based Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. reported that its annual Total Revenue rose from $11.16 million in 2020 to $11.78 million in 2021, and that its Net Loss decleind from $78.39 million in 2020, to $77.7 million in 2021.
On October 21, 2022, after market hours, Accelerate Diagnostics, Inc. filed a current report with the SEC which announced that, pursuant to discussions with the U.S. Food and Drug Administration ("FDA"), the Company would, among other things: "(i) discontinu[e] the U.S. marketing and distribution of [its Accelerate Arc system and related BC Kit (collectively, the "Accelerate Arc Products")] for positive blood culture processing and subsequent identification by mass spectrometry for diagnostic use; (ii) remov[e] and/or correct all U.S. promotional information within the Company's control (e.g., website, labeling, social media, sales associate information, or other promotional material) regarding the diagnostic use of the Accelerate Arc Products as Class I devices or as devices intended as positive blood culture processing devices for subsequent identification of microorganisms by mass spectrometry; and (iii) revis[e]/remov[e] the Company's registration and listing of the Accelerate Arc Products as Class I devices."
Shares of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) declined to 0.89 per share on October 24, 2022.
Those who purchased shares of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About The Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.